The selection of targeted therapies for patients with relapsed or refractory multiple myeloma following treatment with immunomodulatory drugs, proteasome inhibitors and anti-CD38 antibodies will depend on disease characteristics and patient-related factors such as comorbidities and toxicities with prior treatments. The gene discussed is CD38; the disease is AL amyloidosis.